Resmetirom: Off-Label Uses

2 source-based articles maintained by the HealthRX.com Editorial Team.

2articles

2topic areas covered

May 26, 2026latest review

Resmetirom: Off-Label Uses library

Showing 2 of 2 clinical reviews.

Clinical ReviewsMay 26, 2026

Rezdiffra Phase 3 Trial (MAESTRO-NASH) for NASH F2-F3

MAESTRO-NASH data: resmetirom 100mg resolved NASH in 29.9% vs 9.7% placebo at 52 weeks; FDA-approved, not off-label, for F2-F3 fibrosis.

Dosing & MonitoringMay 27, 2026

Rezdiffra Trial Design: MAESTRO-NASH Results & Monitoring

MAESTRO-NASH: 26% on 100mg resmetirom achieved NASH resolution vs 10% placebo at 52 weeks. See dosing, monitoring labs, and imaging schedule for F2-F3 fibrosis.